ELOX - Eloxx Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

26.52M

Cash

4.904M

Avg Qtr Burn

-7.292M

Short % of Float

3.81%

Insider Ownership

0.68%

Institutional Own.

43.97%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ELX-02 Details Rare genetic disease, Alport Syndrome	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZKN-013 Details Rare genetic disease, Junctional epidermolysis bullosa, Recessive dystrophic epidermolysis bullosa	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELX-02 Details Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELX-02 Details Cystic fibrosis, Lung disease, Glabellar lines	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.